Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

Primary Care Amoxicillin Challenge

Phase 4

Withdrawn

Conditions: Amoxicillin Allergy

Interventions: Drug: Amoxicillin

First Posted Date: 2021-12-21

Last Posted Date: 2023-10-18

Lead Sponsor: State University of New York at Buffalo

Registration Number: NCT05165212

Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection

Early Phase 1

Conditions: Gastric Cancer
Helicobacter Pylori Infection
Gastritis

Interventions: Drug: Amoxicillin - high dose dual therapy
Drug: Pylera
Drug: Esomeprazole 40mg

First Posted Date: 2021-10-29

Last Posted Date: 2021-10-29

Lead Sponsor: Hospital da Senhora da Oliveira

Target Recruit Count: 100

Registration Number: NCT05100446

Locations: 🇵🇹
Vítor Bruno Macedo da Silva, Guimarães, Portugal

Early Antibiotics After Aspiration in ICU Patients

Phase 4

Terminated

Conditions: Aspiration
Aspiration Pneumonia

Interventions: Drug: Ceftriaxone
Drug: Amoxicillin clavulanic acid
Drug: Cefepime
Drug: Vancomycin
Drug: Levofloxacin

First Posted Date: 2021-10-15

Last Posted Date: 2024-11-01

Lead Sponsor: UConn Health

Target Recruit Count: 5

Registration Number: NCT05079620

Locations: 🇺🇸
UConn Health, John Dempsey Hospital, Farmington, Connecticut, United States

Helicobacter Pylori Eradication and Follow-up

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Rabeprazole
Drug: Bismuth potassium citrate
Drug: Metronidazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Levofloxacin
Drug: Doxycycline
Drug: Tetracycline

First Posted Date: 2021-09-30

Last Posted Date: 2021-09-30

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 4447

Registration Number: NCT05061732

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin
Drug: Clarithromycin
Drug: Tetracycline
Drug: Metronidazole
Drug: Bismuth Potassium Citrate
Drug: Colloidal Bismuth Pectin
Drug: Vonoprazan fumarate

First Posted Date: 2021-09-20

Last Posted Date: 2023-07-19

Lead Sponsor: Shandong University

Target Recruit Count: 1300

Registration Number: NCT05049902

Locations: 🇨🇳
Maternity and Child Care Health Center of Dezhou, Dezhou, Shandong, China
🇨🇳
Heze Municipal 3rd people's hospital, Heze, Shandong, China
🇨🇳
Qilu hosipital, Jinan, Shandong, China

and more 3 locations

Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era

Not Applicable

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin

First Posted Date: 2021-09-05

Last Posted Date: 2022-02-08

Lead Sponsor: Alexandria University

Target Recruit Count: 233

Registration Number: NCT05035186

Locations: 🇪🇬
Alexandria University., Alexandria, Egypt

Inpatient Penicillin Allergy Delabeling Study

Phase 4

Completed

Conditions: Penicillin Allergy
Penicillin Sensitivity
Penicillin Reaction
Penicillin Intolerance

Interventions: Drug: Graded Oral Amoxicillin Challenge
Other: De-labelling in electronic medical record
Other: Referral to Allergy Immunology/Retention of Allergy Label